United Therapeutics (NASDAQ:UTHR) CEO Sells $4,698,225.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the company’s stock in a transaction dated Monday, September 21st. The stock was sold at an average price of $494.55, for a total transaction of $4,698,225.00. Following the sale, the chief executive officer directly owned 324,443 shares in the company, valued at $160,453,285.65. This represents a 2.84% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

United Therapeutics Price Performance

Shares of UTHR stock opened at $472.21 on Friday. United Therapeutics Corporation has a 1-year low of $409.07 and a 1-year high of $609.35. The firm has a market cap of $20.25 billion, a PE ratio of 16.89, a price-to-earnings-growth ratio of 2.49 and a beta of 0.56. The company has a 50-day moving average of $512.06 and a two-hundred day moving average of $540.50.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.86 by $0.41. The business had revenue of $783.30 million for the quarter, compared to the consensus estimate of $804.65 million. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The business’s revenue was down 1.9% on a year-over-year basis. During the same period in the previous year, the firm earned $6.41 EPS. Sell-side analysts anticipate that United Therapeutics Corporation will post 26.21 EPS for the current fiscal year.

Key United Therapeutics News

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: United Therapeutics is using the remainder of its $2 billion share-repurchase authorization through an accelerated share repurchase. The reduced share count could support earnings per share and provide some underlying demand for the stock. United Therapeutics: Strong Catalyst Flow Bodes Well For Near-Term Growth
• Neutral Sentiment: The company’s prior quarter showed better-than-expected earnings, but revenue declined year over year and fell short of estimates. This leaves investors focused on whether newer products can offset pressure on the established pulmonary-hypertension franchise.
• Negative Sentiment: Goldman Sachs initiated coverage with a Sell rating and a $321 price target, arguing that UTHR trades above its long-term valuation range. The call was a significant negative catalyst because it implies substantial downside from recent trading levels. United Therapeutics, Sagimet drop after Goldman issues Sell ratings
• Negative Sentiment: Goldman also highlighted risks involving payer and reimbursement dynamics, potential generic competition, and uncertain real-world adoption of Jenraldi, a newer growth driver. Investors remain concerned that broader coverage requirements for nebulized Tyvaso could limit future revenue growth. United Therapeutics Slips as New Sell Rating Pressures Shares
• Negative Sentiment: CEO Martine Rothblatt sold 9,500 shares for approximately $4.7 million, reducing her position by 2.84%. The sale may add to sentiment concerns, particularly alongside reports that company insiders have made numerous sales and no purchases recently, although the transaction could also reflect routine personal or tax-related activity. SEC insider transaction filing

Analysts Set New Price Targets

UTHR has been the subject of several research analyst reports. JPMorgan Chase & Co. raised their price target on United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research report on Thursday, July 23rd. Morgan Stanley set a $515.00 price objective on United Therapeutics in a report on Thursday, August 6th. The Goldman Sachs Group assumed coverage on United Therapeutics in a research note on Thursday. They set a “sell” rating and a $321.00 target price on the stock. Royal Bank Of Canada lowered their target price on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a report on Thursday, August 6th. Finally, Weiss Ratings downgraded United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, August 27th. Eleven research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $621.00.

Institutional Investors Weigh In On United Therapeutics

Hedge funds have recently bought and sold shares of the stock. Callan Family Office LLC acquired a new stake in United Therapeutics in the second quarter valued at about $1,217,000. Nicholas Investment Partners LP increased its position in United Therapeutics by 478.5% during the 4th quarter. Nicholas Investment Partners LP now owns 4,553 shares of the biotechnology company’s stock worth $2,218,000 after purchasing an additional 3,766 shares during the period. Canada Pension Plan Investment Board purchased a new position in shares of United Therapeutics during the 2nd quarter worth approximately $3,359,000. Havemeyer Place LP purchased a new position in shares of United Therapeutics during the 4th quarter worth approximately $2,189,000. Finally, Seven Fleet Capital Management LP acquired a new stake in shares of United Therapeutics in the 4th quarter valued at approximately $633,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening conditions, with a primary emphasis on pulmonary arterial hypertension (PAH). The company’s products are designed to improve pulmonary blood flow and reduce the effects of this progressive disease.

United Therapeutics’ PAH portfolio includes Remodulin (treprostinil) injection, Orenitram (treprostinil) extended-release tablets, and Tyvaso (treprostinil), which is available as an inhalation solution and as the Tyvaso DPI dry-powder inhaler.